mitoxantrone
E852340
anthracenedione
antineoplastic agent
chemotherapeutic agent
immunosuppressive agent
topoisomerase II inhibitor
Mitoxantrone is an anthracenedione chemotherapeutic agent used primarily to treat certain cancers and multiple sclerosis by intercalating DNA and inhibiting topoisomerase II.
Observed surface forms (1)
| Surface form | Occurrences |
|---|---|
| Mitoxantrone | 0 |
Statements (50)
| Predicate | Object |
|---|---|
| instanceOf |
anthracenedione
ⓘ
antineoplastic agent ⓘ chemotherapeutic agent ⓘ immunosuppressive agent ⓘ topoisomerase II inhibitor ⓘ |
| approvedBy | US Food and Drug Administration NERFINISHED ⓘ |
| bindsTo | DNA ⓘ |
| developedBy | Lederle Laboratories NERFINISHED ⓘ |
| hasAdverseEffect |
alopecia
ⓘ
amenorrhea ⓘ cardiotoxicity ⓘ congestive heart failure ⓘ myelosuppression ⓘ nausea ⓘ secondary leukemia ⓘ vomiting ⓘ |
| hasApprovalFor | multiple sclerosis (US, restricted use) ⓘ |
| hasATCCode |
L01DB07
ⓘ
L04AX07 ⓘ |
| hasBlackBoxWarning |
cardiotoxicity
ⓘ
secondary acute myeloid leukemia ⓘ |
| hasCASNumber | 65271-80-9 ⓘ |
| hasChemicalFormula | C22H28N4O6 ⓘ |
| hasColor | blue ⓘ |
| hasEliminationHalfLife | about 8–15 days ⓘ |
| hasIUPACName | 1,4-dihydroxy-5,8-bis[[2-[(2-hydroxyethyl)amino]ethyl]amino]-9,10-anthracenedione ⓘ |
| hasMolarMass | 444.48 g/mol ⓘ |
| hasOrigin | synthetic compound ⓘ |
| hasPregnancyCategory | D (US, historical) ⓘ |
| hasRisk | cumulative dose–dependent cardiotoxicity ⓘ |
| inhibits | topoisomerase II ⓘ |
| isAdministeredAs | mitoxantrone hydrochloride ⓘ |
| isContraindicatedIn |
baseline severe cardiac dysfunction
ⓘ
severe hepatic impairment ⓘ |
| isExcretedVia |
bile
ⓘ
feces ⓘ urine ⓘ |
| isMetabolizedBy | hepatic pathways ⓘ |
| isTeratogenic | true ⓘ |
| mechanismOfAction |
DNA intercalation
ⓘ
topoisomerase II inhibition ⓘ |
| routeOfAdministration | intravenous ⓘ |
| usedForTreatmentOf |
acute myeloid leukemia
ⓘ
metastatic breast cancer ⓘ multiple sclerosis ⓘ non-Hodgkin lymphoma NERFINISHED ⓘ progressive relapsing multiple sclerosis ⓘ prostate cancer ⓘ secondary progressive multiple sclerosis ⓘ worsening relapsing-remitting multiple sclerosis ⓘ |
Referenced by (1)
Full triples — surface form annotated when it differs from this entity's canonical label.